Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Linus L. Shen"'
Autor:
Lester A. Mitscher, Linus L. Shen, Pratik Devasthale, Segaran P. Pillai, Ali Keschavarz-Shokri, Robert A. Fecik
Publikováno v:
Journal of Medicinal Chemistry. 48:1229-1236
In pursuit of an apparent literature anomaly, S- and R-6-methyl-6,7-dihydro-2H-benzo[a]quinolizin-2-one-3-carboxylic acids (12 and 22) were synthesized by an unambiguous route from optically active norephedrines, and their antibacterial potencies wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4661acb42207e341a2b7927357e95286
https://doi.org/10.1021/jm0401356
https://doi.org/10.1021/jm0401356
Autor:
Richard F. Clark, Xiaoan Ruan, Xiaoling Xuei, Rolf Wagner, Ping Zhong, Caroline A. David, Steve D. Pratt, Moshe Weitzberg, Candace Black-Schaefer, Linus L. Shen, Peter J. Dandliker, Yingna Cai, Erika E. Englund, Stephan J. Kakavas, Angela M. Nilius, Niru B. Soni, Mai Bui, Melissa M. Daly, Philip J. Merta, Danli L. Towne, Bruce A. Beutel, Linda E. Chovan, Zhensheng Cao, Robert K. Hickman, Anne Y. Saiki, Claude G. Lerner
Publikováno v:
Antimicrobial Agents and Chemotherapy. 47:3831-3839
We report the discovery and characterization of a novel ribosome inhibitor (NRI) class that exhibits selective and broad-spectrum antibacterial activity. Compounds in this class inhibit growth of many gram-positive and gram-negative bacteria, includi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::552703c8ab33220cee707975bca5b007
https://doi.org/10.1128/aac.47.12.3831-3839.2003
https://doi.org/10.1128/aac.47.12.3831-3839.2003
Autor:
Dena M. Hensey-Rudloff, Robert K. Flamm, Darlene J. Balli, Jill Beyer, Linus L. Shen, Laurel S. Almer, Angela M. Nilius, Yingna Cai
Publikováno v:
Antimicrobial Agents and Chemotherapy. 47:3260-3269
ABT-492 demonstrated potent antibacterial activity against most quinolone-susceptible pathogens. The rank order of potency was ABT-492 > trovafloxacin > levofloxacin > ciprofloxacin against quinolone-susceptible staphylococci, streptococci, and enter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d837a2883c5233d3361805e1a009b91
https://doi.org/10.1128/aac.47.10.3260-3269.2003
https://doi.org/10.1128/aac.47.10.3260-3269.2003
Publikováno v:
Molecular Pharmacology. 63:1382-1388
The two known antineoplastic quinoxaline topoisomerase II poisons, XK469 (NSC 697887) and CQS (chloroquinoxaline sulfonamide, NSC 339004), were compared for DNA cleavage site specificity, using purified human topoisomerase IIalpha and human topoisome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::626c982dce1fd0dc1a73430d9a5be99d
https://doi.org/10.1124/mol.63.6.1382
https://doi.org/10.1124/mol.63.6.1382
Autor:
Robert M. Snapka, Ram Ganapathi, Kuan-Chun Huang, Kenneth K. Chan, Linus L. Shen, Shujun Liu, Edith F. Yamasaki, Dale Grabowski, Hanlin Gao
Publikováno v:
Journal of Biological Chemistry. 276:44488-44494
Antineoplastic bis(dioxopiperazine)s, such as meso-2,3-bis(2,6-dioxopiperazin-4-yl)butane (ICRF-193), are widely believed to be only catalytic inhibitors of topoisomerase II. However, topoisomerase inhibitors have little or no antineoplastic activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14f917491b77e2b50858f7a7a7f968f1
https://doi.org/10.1074/jbc.m104383200
https://doi.org/10.1074/jbc.m104383200
Publikováno v:
Medicinal Research Reviews. 20:231-293
Many attempts have been made to prepare analogs of 4-quinolone antibacterial agents bearing novel ring systems, which might retain the favorable properties of these widely used antibacterial agents and at the same time increase activity against multi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f449938fcfc5e0ab1d60b2fd6a220aa4
https://doi.org/10.1002/1098-1128(200007)20:4<231::aid-med1>3.0.co
https://doi.org/10.1002/1098-1128(200007)20:4<231::aid-med1>3.0.co
Publikováno v:
Antimicrobial Agents and Chemotherapy. 43:1574-1577
We have cloned Staphylococcus aureus DNA gyrase and topoisomerase IV and expressed them in Escherichia coli as polyhistidine-tagged proteins to facilitate purification and eliminate contamination by host enzymes. The enzyme preparations had specific
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdd58783e89d4863b45aa55f7f82d4cc
https://doi.org/10.1128/aac.43.7.1574
https://doi.org/10.1128/aac.43.7.1574
Autor:
Anthony K. L. Fung, Linus L. Shen
Publikováno v:
Current Pharmaceutical Design. 5:515-543
Improved potency against multiply resistant streptococci and anaerobic microorganisms relative to current antibiotics has been sought by many laboratories around the world. As one result of attempts to prepare analogs of 4-quinolone anti infectives
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd876497a02753f760cb5cfb37e8f056
https://doi.org/10.2174/1381612805666230110213026
https://doi.org/10.2174/1381612805666230110213026
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 7:1097-1100
A series of hybrid molecules ( 14–16 ) combining certain structural features of both 4-quinolone antimicrobial inhibitors of DNA gyrase and anthracycline inhibitors of mammalian topoisomerase II were prepared synthetically in six chemical steps fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39aa9eae913cbf4be405c3f4bca57d44
https://doi.org/10.1016/s0960-894x(97)00191-1
https://doi.org/10.1016/s0960-894x(97)00191-1
Publikováno v:
Current Pharmaceutical Design. 3:169-176
Abstract: DNA gyrase and topoisomerase IV, the bacterial type II DNA topoisomerases, are known to be the targets of fluoroquinolones. The l1uoroquinolones have rapid bactericidal action derived from their dual actions to inhibit the catalytic activit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2579d3767a6bb123a0876a7b17097ec
https://doi.org/10.2174/138161280302221006114505
https://doi.org/10.2174/138161280302221006114505